Is ZNTL or TENX more profitable?

Tenax Therapeutics' return on equity of -61.54% beat Zentalis Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Zentalis Pharmaceuticals N/A -70.18% -51.46% Tenax Therapeutics N/A -61.54% -57.42%

Does the media favor ZNTL or TENX?

In the previous week, Zentalis Pharmaceuticals had 4 more articles in the media than Tenax Therapeutics. MarketBeat recorded 6 mentions for Zentalis Pharmaceuticals and 2 mentions for Tenax Therapeutics. Zentalis Pharmaceuticals' average media sentiment score of 0.95 beat Tenax Therapeutics' score of 0.00 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tenax Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ACB or TENX?

Tenax Therapeutics has a consensus price target of $14.00, suggesting a potential upside of 700.00%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tenax Therapeutics is more favorable than Aurora Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Tenax Therapeutics 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.56

Does the media favor ACB or TENX?

In the previous week, Aurora Cannabis had 10 more articles in the media than Tenax Therapeutics. MarketBeat recorded 12 mentions for Aurora Cannabis and 2 mentions for Tenax Therapeutics. Aurora Cannabis' average media sentiment score of 0.28 beat Tenax Therapeutics' score of 0.00 indicating that Aurora Cannabis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurora Cannabis 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Tenax Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TENX or SLGL?

In the previous week, Sol-Gel Technologies had 2 more articles in the media than Tenax Therapeutics. MarketBeat recorded 4 mentions for Sol-Gel Technologies and 2 mentions for Tenax Therapeutics. Sol-Gel Technologies' average media sentiment score of 0.42 beat Tenax Therapeutics' score of 0.00 indicating that Sol-Gel Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenax Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sol-Gel Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, TENX or ANTX?

Anthem is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tenax Therapeutics N/A N/A -$52.60M -$1.48 N/A Anthem N/A N/A -$35.17M -$1.07 N/A

Is TENX or ANTX more profitable?

Anthem's return on equity of -53.52% beat Tenax Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tenax Therapeutics N/A -61.54% -57.42% Anthem N/A -53.52% -48.63%

Does the media favor TENX or ANTX?

In the previous week, Anthem had 1 more articles in the media than Tenax Therapeutics. MarketBeat recorded 3 mentions for Anthem and 2 mentions for Tenax Therapeutics. Anthem's average media sentiment score of 0.56 beat Tenax Therapeutics' score of 0.00 indicating that Anthem is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenax Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anthem 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer SBTX or TENX?

Tenax Therapeutics has a consensus price target of $14.00, suggesting a potential upside of 700.00%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tenax Therapeutics is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Tenax Therapeutics 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.56

Which has higher valuation and earnings, SBTX or TENX?

Silverback Therapeutics is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A Tenax Therapeutics N/A N/A -$52.60M -$1.48 N/A

Is SBTX or TENX more profitable?

Silverback Therapeutics' return on equity of -29.62% beat Tenax Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Silverback Therapeutics N/A -29.62% -28.20% Tenax Therapeutics N/A -61.54% -57.42%

Tenax Therapeutics (TENX) Competitors

$1.75 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Compare

TENX vs. ZNTL, ACB, SLGL, ANTX, and SBTX

Should you buy Tenax Therapeutics stock or one of its competitors? Tenax Therapeutics's main competitors and comparable companies include Zentalis Pharmaceuticals (ZNTL), Aurora Cannabis (ACB), Sol-Gel Technologies (SLGL), Anthem (ANTX), and Silverback Therapeutics (SBTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Tenax Therapeutics compare to Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

Zentalis Pharmaceuticals has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

Tenax Therapeutics has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	4.07	-$137.06M	-$1.95	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A

In the previous week, Zentalis Pharmaceuticals had 4 more articles in the media than Tenax Therapeutics. MarketBeat recorded 6 mentions for Zentalis Pharmaceuticals and 2 mentions for Tenax Therapeutics. Zentalis Pharmaceuticals' average media sentiment score of 0.95 beat Tenax Therapeutics' score of 0.00 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentalis Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tenax Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tenax Therapeutics' return on equity of -61.54% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%
Tenax Therapeutics	N/A	-61.54%	-57.42%

1.7% of Tenax Therapeutics shares are owned by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are owned by company insiders. Comparatively, 10.8% of Tenax Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Zentalis Pharmaceuticals presently has a consensus target price of $6.75, indicating a potential upside of 76.24%. Tenax Therapeutics has a consensus target price of $14.00, indicating a potential upside of 700.00%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tenax Therapeutics is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Tenax Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

Summary

Tenax Therapeutics beats Zentalis Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Tenax Therapeutics compare to Aurora Cannabis?

Aurora Cannabis (NASDAQ:ACB) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

Aurora Cannabis has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

Tenax Therapeutics has a net margin of 0.00% compared to Aurora Cannabis' net margin of -32.26%. Aurora Cannabis' return on equity of 4.37% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-32.26%	4.37%	3.45%
Tenax Therapeutics	N/A	-61.54%	-57.42%

47.6% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 0.0% of Aurora Cannabis shares are owned by insiders. Comparatively, 10.8% of Tenax Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Tenax Therapeutics has lower revenue, but higher earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	$314.07M	0.81	-$88.13M	-$1.41	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A

In the previous week, Aurora Cannabis had 10 more articles in the media than Tenax Therapeutics. MarketBeat recorded 12 mentions for Aurora Cannabis and 2 mentions for Tenax Therapeutics. Aurora Cannabis' average media sentiment score of 0.28 beat Tenax Therapeutics' score of 0.00 indicating that Aurora Cannabis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurora Cannabis	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tenax Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tenax Therapeutics has a consensus price target of $14.00, suggesting a potential upside of 700.00%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tenax Therapeutics is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Tenax Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

Summary

Tenax Therapeutics beats Aurora Cannabis on 8 of the 15 factors compared between the two stocks.

How does Tenax Therapeutics compare to Sol-Gel Technologies?

Tenax Therapeutics (NASDAQ:TENX) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Tenax Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, Sol-Gel Technologies has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

Tenax Therapeutics presently has a consensus target price of $14.00, suggesting a potential upside of 700.00%. Sol-Gel Technologies has a consensus target price of $197.50, suggesting a potential upside of 154.08%. Given Tenax Therapeutics' higher possible upside, research analysts clearly believe Tenax Therapeutics is more favorable than Sol-Gel Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenax Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Sol-Gel Technologies has higher revenue and earnings than Tenax Therapeutics. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A
Sol-Gel Technologies	$19.39M	11.26	-$6.13M	-$5.64	N/A

In the previous week, Sol-Gel Technologies had 2 more articles in the media than Tenax Therapeutics. MarketBeat recorded 4 mentions for Sol-Gel Technologies and 2 mentions for Tenax Therapeutics. Sol-Gel Technologies' average media sentiment score of 0.42 beat Tenax Therapeutics' score of 0.00 indicating that Sol-Gel Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenax Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sol-Gel Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tenax Therapeutics has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -910.14%. Sol-Gel Technologies' return on equity of -44.05% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenax Therapeutics	N/A	-61.54%	-57.42%
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%

1.7% of Tenax Therapeutics shares are owned by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are owned by institutional investors. 10.8% of Tenax Therapeutics shares are owned by company insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Sol-Gel Technologies beats Tenax Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Tenax Therapeutics compare to Anthem?

Tenax Therapeutics (NASDAQ:TENX) and Anthem (NASDAQ:ANTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Anthem is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A
Anthem	N/A	N/A	-$35.17M	-$1.07	N/A

Tenax Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, Anthem has a beta of -0.99, meaning that its stock price is 199% less volatile than the broader market.

Tenax Therapeutics presently has a consensus price target of $14.00, suggesting a potential upside of 700.00%. Anthem has a consensus price target of $9.00, suggesting a potential upside of 54.91%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Tenax Therapeutics is more favorable than Anthem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenax Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Anthem had 1 more articles in the media than Tenax Therapeutics. MarketBeat recorded 3 mentions for Anthem and 2 mentions for Tenax Therapeutics. Anthem's average media sentiment score of 0.56 beat Tenax Therapeutics' score of 0.00 indicating that Anthem is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenax Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anthem	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

1.7% of Tenax Therapeutics shares are held by institutional investors. Comparatively, 90.5% of Anthem shares are held by institutional investors. 10.8% of Tenax Therapeutics shares are held by insiders. Comparatively, 22.6% of Anthem shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Anthem's return on equity of -53.52% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenax Therapeutics	N/A	-61.54%	-57.42%
Anthem	N/A	-53.52%	-48.63%

Summary

Anthem beats Tenax Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Tenax Therapeutics compare to Silverback Therapeutics?

Silverback Therapeutics (NASDAQ:SBTX) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

74.9% of Silverback Therapeutics shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by company insiders. Comparatively, 10.8% of Tenax Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Tenax Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

In the previous week, Tenax Therapeutics had 2 more articles in the media than Silverback Therapeutics. MarketBeat recorded 2 mentions for Tenax Therapeutics and 0 mentions for Silverback Therapeutics. Silverback Therapeutics' average media sentiment score of 0.00 equaled Tenax Therapeutics'average media sentiment score.

Company	Overall Sentiment
Silverback Therapeutics	Neutral
Tenax Therapeutics	Neutral

Silverback Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

Silverback Therapeutics' return on equity of -29.62% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
Tenax Therapeutics	N/A	-61.54%	-57.42%

Silverback Therapeutics is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A

Summary

Tenax Therapeutics beats Silverback Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Tenax Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TENX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TENX vs. The Competition

Export

Metric	Tenax Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$65.49M	$12.49B	$7.32B	$12.82B
Dividend Yield	N/A	2.62%	2.54%	10.78%
P/E Ratio	-1.18	789.80	272.91	24.33
Price / Sales	N/A	795.45	639.20	97.25
Price / Cash	N/A	15.47	29.03	36.90
Price / Book	0.17	10.52	11.38	6.42
Net Income	-$52.60M	$2.81B	$3.47B	$348.89M
7 Day Performance	2.34%	2.49%	2.16%	0.51%
1 Month Performance	-87.96%	5.06%	7.59%	4.84%
1 Year Performance	-70.83%	7.26%	25.16%	17.04%

Tenax Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TENX Tenax Therapeutics	2.487 of 5 stars	$1.75 flat	$14.00 +700.0%	-70.8%	$65.49M	N/A	N/A	9	Gap Up
ZNTL Zentalis Pharmaceuticals	3.4643 of 5 stars	$3.68 -0.5%	$6.75 +83.4%	+92.5%	$255.15M	$67.43M	N/A	160	Gap Up
ACB Aurora Cannabis	1.4456 of 5 stars	$3.67 +1.9%	N/A	-21.0%	$238.62M	$247.82M	N/A	1,028	Gap Down
SLGL Sol-Gel Technologies	3.6401 of 5 stars	$79.33 -4.4%	$197.50 +149.0%	+242.9%	$237.97M	$19.39M	N/A	50	Earnings Report Gap Up
ANTX Anthem	2.0142 of 5 stars	$5.97 +4.2%	$9.00 +50.8%	+411.9%	$226.04M	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TENX) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tenax Therapeutics (TENX) Competitors

TENX vs. ZNTL, ACB, SLGL, ANTX, and SBTX

How does Tenax Therapeutics compare to Zentalis Pharmaceuticals?

Summary

How does Tenax Therapeutics compare to Aurora Cannabis?

Summary

How does Tenax Therapeutics compare to Sol-Gel Technologies?

Summary

How does Tenax Therapeutics compare to Anthem?

Summary

How does Tenax Therapeutics compare to Silverback Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TENX vs. The Competition

Tenax Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tenax Therapeutics (TENX) Competitors

TENX vs. ZNTL, ACB, SLGL, ANTX, and SBTX

How does Tenax Therapeutics compare to Zentalis Pharmaceuticals?

Which has more volatility & risk, ZNTL or TENX?

Which has preferable earnings and valuation, ZNTL or TENX?

Does the media favor ZNTL or TENX?

Is ZNTL or TENX more profitable?

Do institutionals and insiders have more ownership in ZNTL or TENX?

Do analysts recommend ZNTL or TENX?

Summary

How does Tenax Therapeutics compare to Aurora Cannabis?

Which has more risk and volatility, ACB or TENX?

Is ACB or TENX more profitable?

Do insiders and institutionals hold more shares of ACB or TENX?

Which has better valuation & earnings, ACB or TENX?

Does the media favor ACB or TENX?

Do analysts rate ACB or TENX?

Summary

How does Tenax Therapeutics compare to Sol-Gel Technologies?

Which has more risk & volatility, TENX or SLGL?

Do analysts recommend TENX or SLGL?

Which has preferable earnings and valuation, TENX or SLGL?

Does the media favor TENX or SLGL?

Is TENX or SLGL more profitable?

Do institutionals & insiders hold more shares of TENX or SLGL?

Summary

How does Tenax Therapeutics compare to Anthem?

Which has stronger valuation and earnings, TENX or ANTX?

Which has more volatility & risk, TENX or ANTX?

Do analysts recommend TENX or ANTX?

Does the media favor TENX or ANTX?

Do institutionals and insiders hold more shares of TENX or ANTX?

Is TENX or ANTX more profitable?

Summary

How does Tenax Therapeutics compare to Silverback Therapeutics?

Do institutionals and insiders have more ownership in SBTX or TENX?

Do analysts prefer SBTX or TENX?

Does the media refer more to SBTX or TENX?

Which has more volatility & risk, SBTX or TENX?

Is SBTX or TENX more profitable?

Which has higher valuation and earnings, SBTX or TENX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TENX vs. The Competition

Tenax Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools